Abbott Laboratories (NYSE:ABT) detailed fourth-quarter 2025 results and outlined its 2026 outlook on its earnings conference call, emphasizing continued momentum in medical devices, a transition plan ...
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes ...
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...
The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to ...
HKUMed reveals that combining novel caFFR imaging technology with glucose lowering drug effectively protects the heart of ...
Researchers from the University of Hong Kong said on Tuesday combining imaging technology with an anti-diabetic drug ...
SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...
Q: A lot of my friends are doing Dry January but I don’t drink enough to bother with it. Still, I like the idea of giving up ...
This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in individuals with type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback